Company profile

DELCATH SYSTEMS, INC.

NASDAQ:DCTHMedical/Dental Instruments

Drug pipeline (1)

Asset	Stage	Revenue	Trials	Status
HEPZATO	approved	$27.2MQ2 2026	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (7)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06875128	phase2	recruiting	2026-01-29	2029-05-01	Delcath Systems Inc.	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06607458	phase2	recruiting	2025-08-05	2026-12-01	Delcath Systems Inc.	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT00324727	phase3	completed	2006-02-01	2012-08-01	Delcath Systems Inc.	Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
NCT00096083	phase2	completed	2004-09-01	2012-08-01	Delcath Systems Inc.	Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
NCT02415036	phase2	terminated	2014-06-01	2018-10-01	Delcath Systems Inc.	Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

FDA applications (1)

Application

Approved

Type

Applicant

Products

NDA 201848

2023-08-14

NDA

DELCATH SYSTEMS INC